Acute lymphoblastic leukemia (ALL) is a form of blood cancer that specifically affects the white blood cells or the lymphoblasts. The bone marrow that is responsible for the production of these lymphoblasts is primarily affected in this disease, which results in the uncontrollable production of abnormal lymphoblasts. Acute leukemia develops and progresses at a rapid pace, thus requiring immediate treatment upon detection. As the production of abnormal cancerous cells increases, the growth of healthy white blood cells decreases which eventually results in a weakened immune system. The common symptoms of ALL include fatigue, bleeding from gum and nose, swollen lymph nodes and weight loss. The treatment for acute lymphoblastic leukemia involves various drugs and therapies that target the bone marrow and destroy cancerous cells, thereby restoring the normal functioning of the body.
It was estimated that about 95,764 people living in the United States had acute lymphocytic leukemia in 2016, as per the National Cancer Institute. The cause of this disease is not yet known, however, family history and genetic factors are the probable risk factors. There are two main types of acute lymphoblastic leukemia, that is, B-cell ALL and T-cell ALL. The acute lymphoblastic leukemia treatment market is anticipated to record a CAGR of around 5.5% over the forecast period, i.e., 2019-2027. The market is segmented by treatment, by leukemia type, by end user, by distribution channel and by region. On the basis of treatment, the market is further segmented into chemotherapy, radiation therapy, immunotherapy, bone marrow transplant and targeted therapy, out of which, the chemotherapy segment is anticipated to hold the largest share in the acute lymphoblastic leukemia treatment market as a result of high revenue generation by chemotherapy as compared to other treatment methods. Cancer causes about 1 in every 6 deaths and was responsible for around 9.6 million deaths globally in 2018 according to the World Health Organization. The high prevalence of cancer among people results in the need for effective treatment methods such as chemotherapy. The high rate of prescription of this therapy along with availability of a large number of chemotherapy drugs in the market are addition factors estimated to support the growth of this market during the forecast period. DOWNLOAD SAMPLE REPORT HERE
According to the National Cancer Institute, around 5,930 new cases of Acute Lymphocytic Leukemia (ALL) are estimated to occur in 2019, with around 1,500 cases of deaths due to ALL in the same year in United States. The high number of cases of this form of leukemia that affect both children and adults requires effective treatment methods, a factor which is anticipated to result in a significant market growth.
Advancements in the medical industry that leads to development of highly effective and accurate treatment methods for cancer are estimated to drive the market growth during the forecast period. The demand for improved cancer treatment is increasing on account of growing incidences of cancer across the world. Based on the 2009-2015 data from the SEER program by National Cancer Institute, around 68.6% people with acute lymphoblastic leukemia during the time period survived 5 or more years after being diagnosed with the condition. The increasing requirement for cost effective and advanced treatment methods for acute lymphoblastic leukemia are additional factors anticipated to support the market growth.
The research, development and approval of any treatment method takes several years. Moreover, the government policies regarding clinical testing and approval of cancer drugs and treatments is highly strict. These factors are estimated to limit the market growth.
Our in-depth analysis of the acute lymphoblastic leukemia treatment market includes the following segments:
On the basis of regional analysis, the acute lymphoblastic leukemia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
By region, the market in North America is anticipated to hold the principal share in acute lymphoblastic leukemia treatment market on account of the ease of availability of medical treatments in the region. Additionally, the presence of major pharmaceutical companies and skilled medical professionals in hospitals are a few more factors estimated to contribute towards the growth of market in this region in the upcoming years. The market in Asia-Pacific region is anticipated to observe the highest growth rate during the forecast period which can be attributed to the increasing government investments on improving healthcare infrastructure and a high population base with rising cases of cancer among them, especially in countries such as Japan, China and India.
The acute lymphoblastic leukemia treatment market is further classified on the basis of region as follows:
Top Featured Companies Dominating the Market
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization